Intelligence Platform

Patents

Browse 379 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10077444

Compositions and methods for inhibiting expression of the LECT2 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10060921

Methods of treating transthyretin (TTR) mediated amyloidosis

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10030244

Serpina1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9999673

PEGylated lipids and their use for drug delivery

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9982263

Conserved HBV and HCV sequences useful for gene silencing

Alnylam Pharmaceuticals, Inc. · Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9970006

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) gene

Alnylam Pharmaceuticals, Inc. · Granted Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963700

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957507

Compositions and methods for inhibiting expression of mutant EGFR gene

Alnylam Pharmaceuticals, Inc. · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9944671

Compositions and methods directed to treating liver fibrosis

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9932593

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9902955

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868950

Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gen

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9867882

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9850488

Complement component C5 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9822365

Compositions and methods for inhibiting expression of the PCSK9 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9796974

Modified RNAi agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9783806

TMPRSS6 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9771591

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9708615

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9701963

Complement component C5 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9687448

Nucleic acid lipid particle formulations

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9682922

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9631193

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9587240

Compositions and methods for inhibiting expression of a target gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted